Program
cemiplimab
Also written as “Cemiplimab”, “REGN2810” and “REGN2810/chemo/ipi”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Basal Cell · Squamous Cell Carcinoma of Head and Neck · Neoplasm Metastasis, led by 7 companies.
Drug pageCemiplimab: every studyMany companies study it; this page follows only the 42 they lead. All 135 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 3516 open or running | phase 3since Mar 3, 2017 | Feb 2, 2015 | Mar 22, 2027phase 3 · NCT06246916 |
| BioNTechits history only | 20 open or running | phase 2since Apr 21, 2020 | Apr 21, 2020 | none ahead |
| Maia Biotechnologyits history only | 11 open or running | phase 3since Mar 20, 2025 | Mar 20, 2025 | Jul 31, 2027phase 3 · NCT06908304 |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 2since May 22, 2023 | May 22, 2023 | none ahead |
| Sanofiits history only | 10 open or running | phase 2since Jun 19, 2017 | Jun 19, 2017 | none ahead |
| SillaJenits history only | 10 open or running | phase 2since Sep 19, 2017 | Sep 19, 2017 | none ahead |
| Vyriadits history only | 11 open or running | phase 2since Feb 25, 2020 | Feb 25, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Regeneron Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 22 earlier studies, Feb 2, 2015 to Apr 15, 2020.
- Jun 9, 2018Named cemiplimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, REGN2810
- Nov 6, 2020Phase 2 study in Advanced Solid TumorsNCT04626635 · 548 enrolled · United States, France, Israel and more
- Jan 24, 2022Phase 1 study in Neoplasm MetastasisNCT05259709 · 22 enrolled · Netherlands
- Sep 23, 2022Phase 2 study in Advanced Non-Small Cell Lung CancerNCT05557591 · 51 enrolled · United States, Georgia, Germany and more
- Nov 9, 2023Phase 2 study in MelanomaNCT06190951 · 151 enrolled · United States, Australia, Austria and more
- Jan 30, 2024Phase 3 study in MelanomaNCT06246916 · 560 planned · United States, Canada
- Apr 22, 2024Phase 2 study in Cutaneous Squamous Cell CarcinomaNCT06384820
- May 9, 2024Phase 2 study in MelanomaNCT06413680 · 240 planned · United States
- Jun 6, 2024Phase 1 study in Carcinoma, Ovarian EpithelialNCT06469281 · 90 planned · United States
- Sep 3, 2024Phase 3 study in Skin NeoplasmsNCT06585410 · 369 planned · United States, Australia
- Jan 6, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06769698 · 120 planned · United States, Australia, France and more
- Feb 24, 2025Phase 2 study in MelanomaNCT06848088 · 28 enrolled · United States, Ireland
- Apr 28, 2026Phase 2 study in GliomaNCT07567469 · 120 planned
- Sep 1, 2026Phase 2 study in Skin NeoplasmsNCT07808515 · 135 planned
- Nov 10, 2026Primary completion moved from 2029-10-10 to 2030-10-09Date moved laterphase 2 · +12 months · NCT06848088
Ahead
- Nov 2, 2026Primary completion: phase 2 study in MelanomaNCT06190951
- Nov 13, 2026Primary completion: phase 2 study in Advanced Solid TumorsNCT04626635
- Mar 22, 2027Primary completion: phase 3 study in MelanomaNCT06246916
- Apr 29, 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT05259709
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 35 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07808515Skin Neoplasms | 2 | Not yet recruiting | Nov 13, 2030 | 135 |
| NCT07567469Glioma | 2 | Not yet recruiting | Aug 27, 2032 | 120 |
| NCT06848088Melanoma · United States, Ireland | 2 | Active, not recruiting | Oct 9, 2030 | 28 |
| NCT06769698Squamous Cell Carcinoma of Head and Neck · United States, Australia, France and more | 2 | Recruiting | Jun 4, 2028 | 120 |
| NCT06585410Skin Neoplasms · United States, Australia | 3 | Recruiting | May 3, 2030 | 369 |
| NCT06469281Carcinoma, Ovarian Epithelial · United States | 1 | Recruiting | May 27, 2030 | 90 |
| NCT06413680Melanoma · United States | 2 | Recruiting | Feb 3, 2030 | 240 |
| NCT06384820Cutaneous Squamous Cell Carcinoma | 2 | Withdrawn | Jun 8, 2026 | 0 |
| NCT06246916Melanoma · United States, Canada | 3 | Recruiting | Mar 22, 2027 | 560 |
| NCT06190951Melanoma · United States, Australia, Austria and more | 2 | Active, not recruiting | Nov 2, 2026 | 151 |
| NCT05557591Advanced Non-Small Cell Lung Cancer · United States, Georgia, Germany and more | 2 | Active, not recruiting | Jan 26, 2028 | 51 |
| NCT05259709Neoplasm Metastasis · Netherlands | 1 | Active, not recruiting | Apr 29, 2027 | 22 |
| NCT04626635Advanced Solid Tumors · United States, France, Israel and more | 2 | Active, not recruiting | Nov 13, 2026 | 548 |
| NCT04373083Hodgkin Disease | 2 | Withdrawn | Dec 20, 2022 | 0 |
| NCT04154943Cutaneous Squamous Cell Carcinoma · United States, Australia, Germany | 2 | Completed | Dec 1, 2021 | 79 |
| NCT03969004Cutaneous Squamous Cell Carcinoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Jan 7, 2028 | 415 |
| NCT03916627Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | Mar 31, 2025 | 65 |
| NCT03889912Carcinoma, Basal Cell · United States, Australia, Netherlands | 1 | Completed | Nov 13, 2025 | 97 |
| NCT03690869Central Nervous System Neoplasms · United States | 2 | Terminated | May 10, 2023 | 57 |
| NCT03580694Carcinoma, Non-Small-Cell Lung · United States | 1 | Terminated | Dec 4, 2019 | 17 |
| NCT03564340Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | May 10, 2027 | 890 |
| NCT03515629Carcinoma, Non-Small-Cell Lung · United States, Italy, Lithuania | 3 | Terminated | Jul 29, 2021 | 5 |
| NCT03430063Advanced Non-Small Cell Lung Carcinoma · United States, Belgium, France and more | 2 | Terminated | Oct 27, 2021 | 28 |
| NCT03409614Carcinoma, Non-Small-Cell Lung · United States, Austria, China and more | 3 | Completed | Feb 27, 2025 | 789 |
| NCT03257267Carcinoma, Squamous Cell · United States, Australia, Belgium and more | 3 | Completed | Mar 15, 2021 | 608 |
| NCT03233139Advanced Malignancies · Japan | 1 | Active, not recruiting | Sep 30, 2027 | 146 |
| NCT03198130Recurrent Squamous Cell Carcinoma of Head · Korea, Republic of, United Kingdom | 1 | Completed | Jun 27, 2019 | 33 |
| NCT03132636Carcinoma, Basal Cell · United States, Austria, Belgium and more | 2 | Completed | May 20, 2021 | 138 |
| NCT03088540Carcinoma, Non-Small-Cell Lung · Australia, Belarus, Brazil and more | 3 | Completed | Apr 18, 2025 | 712 |
| NCT03002376Melanoma · Korea, Republic of, Netherlands, Serbia and more | 1 | Completed | Mar 5, 2019 | 47 |
| NCT03005782Neoplasms · United States, Australia, Ireland and more | 1 | Completed | Apr 2, 2024 | 333 |
| NCT02760498Advanced Cutaneous Squamous Cell Carcinoma · United States, Australia, Brazil and more | 2 | Completed | Oct 18, 2023 | 432 |
| NCT02651662Recurrence · United States, Austria, Germany and more | 1 | Completed | Apr 29, 2026 | 105 |
| NCT02520245Advanced Malignancies · United States | 1 | Withdrawn | Nov 2023 | 0 |
| NCT02383212Advanced Cancer · United States, Australia, Spain | 1 | Completed | Nov 18, 2019 | 398 |
How it is read
Names in the registry
- “Cemiplimab”, 23 entries
- “cemiplimab”, 9 entries
- “REGN2810”, 4 entries
- “REGN2810/chemo/ipi”, 2 entries
- “Fianlimab+cemiplimab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Melanoma, 7 studies
- Carcinoma, Basal Cell, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.